Lesson plan
Diranersen
Diranersen ( ; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease. It is given by intrathecal injection. The drug is under development by Ionis Pharmaceuticals and Biogen. As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease. Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65% and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial. This degree of slowing is on par with that of existing anti-amyloid antibodies. The drug is one of the most clinically advanced anti-tau drugs under development.
Article summary
Diranersen ( ; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease. It is given by intrathecal injection. The drug is under development by Ionis Pharmaceuticals and Biogen. As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease. Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65% and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial. This degree of slowing is on par with that of existing anti-amyloid antibodies. The drug is one of the most clinically advanced anti-tau drugs under development.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.